4.3 Article

World Health Organization Group 5 Pulmonary Hypertension

Journal

CLINICS IN CHEST MEDICINE
Volume 34, Issue 4, Pages 753-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2013.08.005

Keywords

Sarcoidosis; Lymphangioleiomyomatosis; Pulmonary Langerhans cell histiocytosis; Renal failure; Splenectomy; Fibrosing mediastinitis; Myeloproliferative disorders; Metabolic disorders

Funding

  1. Pfizer
  2. Gilead
  3. Actelion
  4. United Therapeutics
  5. Novartis
  6. Medtronics
  7. Bayer
  8. Ikaria
  9. Aires

Ask authors/readers for more resources

World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, and disorders leading to pulmonary vascular occlusion or compression. This article discusses common pathogenic mechanisms leading to group 5 PH, followed by a detailed overview of epidemiology, pathogenesis, and disease-specific management of the individual group 5 conditions. Off-label use of vasomodulatory therapies, typically indicated for pulmonary arterial hypertension (WHO group 1 PH), in group 5 conditions is also discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available